ATE499113T1 - Influenzavirus-impfstoffzusammensetzung - Google Patents

Influenzavirus-impfstoffzusammensetzung

Info

Publication number
ATE499113T1
ATE499113T1 AT05077465T AT05077465T ATE499113T1 AT E499113 T1 ATE499113 T1 AT E499113T1 AT 05077465 T AT05077465 T AT 05077465T AT 05077465 T AT05077465 T AT 05077465T AT E499113 T1 ATE499113 T1 AT E499113T1
Authority
AT
Austria
Prior art keywords
influenza virus
vaccine composition
virus vaccine
antigen
dose
Prior art date
Application number
AT05077465T
Other languages
English (en)
Inventor
Hondt Erik D
Norbert Hehme
Original Assignee
Smithkline Beecham Biolog
Saechsisches Serumwerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE499113(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog, Saechsisches Serumwerk filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of ATE499113T1 publication Critical patent/ATE499113T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05077465T 1999-09-30 2000-09-27 Influenzavirus-impfstoffzusammensetzung ATE499113T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923176.3A GB9923176D0 (en) 1999-09-30 1999-09-30 Novel composition

Publications (1)

Publication Number Publication Date
ATE499113T1 true ATE499113T1 (de) 2011-03-15

Family

ID=10861908

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00966084T ATE309821T1 (de) 1999-09-30 2000-09-27 Influenzavirus-impfstoffzusammensetzung
AT05077465T ATE499113T1 (de) 1999-09-30 2000-09-27 Influenzavirus-impfstoffzusammensetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00966084T ATE309821T1 (de) 1999-09-30 2000-09-27 Influenzavirus-impfstoffzusammensetzung

Country Status (15)

Country Link
US (2) US7238349B1 (de)
EP (4) EP1618889B8 (de)
JP (4) JP2003510291A (de)
AT (2) ATE309821T1 (de)
AU (1) AU774921B2 (de)
BR (1) BR0014386A (de)
CA (2) CA2386014C (de)
CY (2) CY1111908T1 (de)
DE (3) DE60045668D1 (de)
DK (2) DK1618889T3 (de)
ES (2) ES2359982T3 (de)
GB (1) GB9923176D0 (de)
HK (1) HK1048434B (de)
PT (1) PT1618889E (de)
WO (1) WO2001022992A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP2005523698A (ja) 2002-04-26 2005-08-11 メディミューン・ヴァクシンズ・インコーポレーテッド インフルエンザウイルスの生産用多重プラスミドシステム
US20050106178A1 (en) * 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
AU2012201973B2 (en) * 2003-02-25 2014-05-22 Medimmune, Llc Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2517181C (en) 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
DK2179744T3 (da) 2004-09-09 2011-01-31 Novartis Vaccines & Diagnostic Nedsættelse af potentielle iatrogene risici forbundet med influenzavacciner
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
CA2602456A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945252B1 (de) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Squalen adjuvans-impfstoff influenza oberflächen-antigene gereinigt aus in zellkulturen gezüchteten influenza-viren enthaltend
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
AU2006310341B2 (en) * 2005-11-04 2011-01-06 Novartis Vaccines And Diagnostics Limited Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ568212A (en) 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
NZ567980A (en) * 2005-11-04 2012-01-12 Novartis Vaccines & Diagnostic Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
DK2478916T3 (da) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US9072701B2 (en) * 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2035035A2 (de) 2006-06-09 2009-03-18 Novartis AG Immunogene zusammensetzungen für streptococcus agalactiae
DK2032163T3 (da) * 2006-06-15 2013-03-25 Novartis Ag Multidoseringsplan for en adjuvant-sparende influenzavaccination
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
CN105727276A (zh) * 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
EP2043682B1 (de) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenzaimpfstoff
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
NZ577405A (en) * 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2674486A1 (de) 2007-06-18 2013-12-18 MedImmune, LLC Influenza-B-Viren mit Veränderungen im Hämagglutininpolypeptid
CN101085348B (zh) * 2007-06-18 2010-08-18 南京农业大学 用于禽流感灭活抗原的鼻腔免疫复合佐剂
US20100183671A1 (en) 2007-06-27 2010-07-22 Novartis Vaccines & Diagnostics GmbH & Co., KG Low-additive influenza vaccines
EP2173866A2 (de) * 2007-06-29 2010-04-14 Avianax, LLC Herstellung eines impfstoffs für krankheitserregende vogelvirenerkrankungen
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en) * 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8668904B2 (en) 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2710480A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
NZ587798A (en) * 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
EP2278997B1 (de) * 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsions-grippeimpfstoff
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
JP5712126B2 (ja) 2008-06-25 2015-05-07 ノバルティス アーゲー 遅延型追加刺激免疫処置に対する迅速な応答
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
CN105727281A (zh) 2009-02-10 2016-07-06 诺华股份有限公司 具有减少量的角鲨烯的流感疫苗
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
BE1019643A3 (fr) 2009-04-27 2012-09-04 Novartis Ag Vaccins de protection contre la grippe.
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
US9341623B2 (en) * 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
EP2485753A4 (de) 2009-10-09 2013-12-11 Cbio Ltd Chaperonin-10-varianten
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PL2380558T5 (pl) 2009-12-03 2020-10-05 Novartis Ag Wytwarzanie emulsji w układzie komory oddziaływań i komory przeciwciśnieniowej do mikrofluidyzacji
EP2356983B1 (de) 2009-12-03 2013-02-20 Novartis AG Komponentenzirkulation während der Homogenisierung von Emulsionen
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
KR101625623B1 (ko) 2009-12-03 2016-05-31 노파르티스 아게 백신 보조제 제조 중의 친수성 여과
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
TR201905021T4 (tr) 2010-05-12 2019-05-21 Novartis Ag Skualen içeren bir suda yağ emülsiyonunun üretimi.
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2825403C (en) 2011-01-27 2023-02-21 Gamma Vaccines Pty Limited Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
JP2016539314A (ja) 2011-12-12 2016-12-15 ノバルティス アーゲー インフルエンザウイルス血球凝集素のためのアッセイ法
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
CN105534969B (zh) 2012-03-23 2019-04-05 皮特尼制药股份有限公司 用于癌症治疗的激酶抑制剂
IN2014DN10408A (de) 2012-06-05 2015-08-14 Univ Australian
BR112015002268A2 (pt) 2012-08-03 2017-11-07 Sanofi Pasteur produção de vírus influenza infecciosos
NZ631523A (en) 2012-08-06 2017-03-31 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
DK2931296T3 (da) 2012-12-17 2019-06-03 Newsouth Innovations Pty Ltd Sygdomsbehandling, der involverer mucin
CA2934958A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2523614C1 (ru) * 2013-04-09 2014-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Вакцина против гриппа и способ ее получения
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US10286062B2 (en) * 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
JP5412603B1 (ja) * 2013-07-31 2014-02-12 株式会社クラレ 透明性、熱割れ現象抑制に優れるポリビニルアセタールフィルム
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
JP6903046B2 (ja) 2015-03-26 2021-07-14 ジーピーエヌ ワクチン プロプライアタリー リミティド 連鎖球菌ワクチン
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3320343B1 (de) 2015-07-07 2020-09-02 Seqirus UK Limited Verfahren zur quantifizierung von immunogenem hämagglutinin
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
US20230218526A1 (en) 2020-06-30 2023-07-13 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants
CN111803625B (zh) * 2020-09-09 2020-12-18 天津中逸安健生物科技有限公司 一种亚单位流感疫苗裂解剂及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) * 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
EP0684838A1 (de) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation 3-0-deacylierte monophoshoryl lipid a enthaltende influenzaimpfstoffzusammensetzungen
ES2109685T5 (es) * 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
US6387378B1 (en) * 1993-09-09 2002-05-14 George P. Shibley Device for storage and mucosal delivery of biological or pharmaceutical materials to animals
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3836874B2 (ja) * 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AU1145699A (en) * 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
NZ504894A (en) * 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
AU3099599A (en) * 1998-03-20 1999-10-11 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ES2293923T3 (es) * 1999-09-24 2008-04-01 Glaxosmithkline Biologicals S.A. Vacuna intranasal contra el virus influenza.
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CA2602456A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2043682B1 (de) * 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenzaimpfstoff
CN105727276A (zh) * 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition

Also Published As

Publication number Publication date
ES2359982T3 (es) 2011-05-30
EP1618889A2 (de) 2006-01-25
EP1618889B8 (de) 2011-04-20
CA2616210A1 (en) 2001-04-05
PT1618889E (pt) 2011-05-10
DE60045668D1 (de) 2011-04-07
EP1618889A3 (de) 2006-06-14
WO2001022992A2 (en) 2001-04-05
JP2014205726A (ja) 2014-10-30
JP2003510291A (ja) 2003-03-18
EP3103473A1 (de) 2016-12-14
DK1618889T3 (da) 2011-06-06
DE60024112T2 (de) 2006-08-24
CY2011008I2 (el) 2014-04-09
CA2386014A1 (en) 2001-04-05
AU774921B2 (en) 2004-07-15
HK1048434A1 (en) 2003-04-04
US20070141078A1 (en) 2007-06-21
AU7660200A (en) 2001-04-30
GB9923176D0 (en) 1999-12-01
JP2008001725A (ja) 2008-01-10
CY1111908T1 (el) 2014-04-09
US7238349B1 (en) 2007-07-03
JP2012021030A (ja) 2012-02-02
EP1618889B1 (de) 2011-02-23
EP1216053B1 (de) 2005-11-16
EP2269637A1 (de) 2011-01-05
CA2386014C (en) 2014-05-13
DE122011100035I1 (de) 2011-12-15
WO2001022992A3 (en) 2001-05-17
CY2011008I1 (el) 2014-04-09
ATE309821T1 (de) 2005-12-15
DK1216053T3 (da) 2006-03-20
BR0014386A (pt) 2002-06-18
EP1216053A2 (de) 2002-06-26
DE60024112D1 (de) 2005-12-22
CA2616210C (en) 2014-05-06
HK1048434B (zh) 2006-07-28
ES2250193T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
JP2011504486A5 (de)
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
EP1270016A4 (de) Aidsvirus-impfstoff unter verwendung eines sendaivirus-vektors
GB2386072A (en) Novel vaccine
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
MY153290A (en) Multivalent avian influenza vaccines
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
ATE471990T1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE431745T1 (de) Ltb4 als adjuvans für impfstoffe
WO2008115785A3 (en) Multivalent avian influenza vaccines and methods
MX2023011129A (es) Mutantes del virus de la influenza b y usos de los mismos.
MX2024005483A (es) Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.
WO2004034956A3 (de) 8-plasmid methode mit mutiertem ha gen zur herstellung eines influenza-impfstoffes
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania
UY27621A1 (es) " antígeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1618889

Country of ref document: EP